Haleon Buys Back £10M in Shares
Ticker: HLNCF · Form: 6-K · Filed: Sep 11, 2024 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, treasury-shares
TL;DR
Haleon just bought back 1.25M shares for £10M. Treasury shares incoming.
AI Summary
Haleon plc announced on September 11, 2024, that it repurchased 1,250,000 of its own ordinary shares at an average price of approximately £8.00 per share. The total cost of these repurchases was approximately £10,000,000. These shares were bought on the London Stock Exchange and will be held as treasury shares.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share, which may be viewed positively by investors.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases, which is a common corporate action with no immediate negative implications.
Key Numbers
- £10.0M — Share Repurchase Cost (Total amount spent by Haleon on buying back its own shares.)
- 1.25M — Shares Repurchased (Number of ordinary shares Haleon bought back.)
Key Players & Entities
- Haleon plc (company) — Registrant
- 1,250,000 (dollar_amount) — Number of shares repurchased
- £8.00 (dollar_amount) — Average price per share
- £10,000,000 (dollar_amount) — Total cost of repurchases
- September 11, 2024 (date) — Date of transaction
FAQ
What was the total number of Haleon plc ordinary shares repurchased?
Haleon plc repurchased 1,250,000 ordinary shares.
On what date did Haleon plc conduct this transaction in its own shares?
The transaction in its own shares occurred on 11 September 2024.
What was the approximate average price per share for the repurchased shares?
The average price per share was approximately £8.00.
What is the total approximate cost of the share repurchase program announced?
The total approximate cost of the share repurchase program is £10,000,000.
Where were these shares repurchased?
The shares were repurchased on the London Stock Exchange.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-09-11 14:01:39
Filing Documents
- a8386d.htm (6-K) — 28KB
- 0001654954-24-011747.txt ( ) — 30KB
From the Filing
IN OWN SHARES a8386d UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description         99.1  11 September 2024 – “Transaction in Own Shares”   99.1   Haleon plc:   Transaction in own shares   11 September 2024:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under its share buyback programme announced on 1 August 2024   (the "Buyback Programme").   Date of purchase: 11 September 2024 Number of Shares purchased: 506,000 Highest price paid per Share (p): 396.6000 Lowest price paid per Share (p): 393.3000 Volume weighted average price paid per Share (p): 395.0303   Following the settlement of the above, the Company's registered share capital consists of 9,120,364,772 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/8383D_1-2024-9-11.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Sonya Ghobrial   +44 7392 784784 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Gemma Thomas +44 7985 175048 Emma White +44 7823 523562     Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .    SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 11, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary